Clinic
Sentara Hospitals
Sentara Hospitals was paid $57.85M by Medicaid between Jan 2018 and Dec 2024, across 321 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoSENTARA HOSPITALS
SUFFOLK, VA 23434
SUFFOLK, VA 23434
33aNPI1376540138assigned 07/07/2005
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$57.85M
24GClaims1,659,461
24DCodes billed321
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#2 of 6
Median peer was paid$52.40M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 153,795 | $3.20M | |
| 2019 | 207,324 | $5.13M | |
| 2020 | 201,613 | $7.68M | |
| 2021 | 258,386 | $9.31M | |
| 2022 | 294,010 | $10.55M | |
| 2023 | 351,345 | $13.94M | |
| 2024incomplete | 192,988 | $8.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 68,908 | 58,679 | $11.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 53,108 | 42,686 | $8.17M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 24,367 | 17,943 | $6.63M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 31,793 | 25,417 | $4.83M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.3% | 20,257 | 17,903 | $3.08M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 49,334 | 12,402 | $2.48M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 13,812 | 11,769 | $2.37M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 12,853 | 10,760 | $2.10M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.9% | 4,896 | 4,263 | $1.10M |
| G0378 | Hospital observation service, per hour | 1.4% | 4,234 | 3,013 | $785K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 6,321 | 5,464 | $764K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 19,687 | 6,801 | $723K |
309 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 2,857 | $672K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 4,201 | $665K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,430 | $649K |
| 59025 | Fetal non-stress test | <1% | 3,003 | $553K |
| 97161 | <1% | 4,963 | $548K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 823 | $458K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,702 | $442K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,903 | $403K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,107 | $399K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,541 | $376K |
| J3490 | Unclassified drugs | <1% | 200,976 | $317K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,075 | $302K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,556 | $302K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 19,389 | $291K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69,660 | $258K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,867 | $239K |
| 97162 | <1% | 2,810 | $223K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,267 | $217K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 32,441 | $209K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,115 | $199K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,995 | $197K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,212 | $190K |
| 0240U | <1% | 3,064 | $186K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,258 | $174K |
| 93971 | <1% | 2,290 | $174K | |
| 76642 | <1% | 1,651 | $169K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,515 | $164K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,514 | $164K |
| 76830 | Ultrasound, transvaginal | <1% | 2,136 | $160K |
| 10060 | <1% | 1,464 | $155K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,284 | $150K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,761 | $132K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 675 | $130K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,550 | $126K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,236 | $126K |
| 72141 | <1% | 602 | $125K | |
| 93017 | <1% | 1,658 | $125K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 596 | $123K |
| 70491 | <1% | 741 | $122K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 45,722 | $109K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,890 | $104K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,984 | $100K |
| 93970 | <1% | 987 | $99K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,419 | $97K |
| 76770 | <1% | 819 | $90K | |
| 59050 | <1% | 533 | $90K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,479 | $87K |
| 97597 | <1% | 1,670 | $73K | |
| 80047 | <1% | 19,024 | $72K | |
| 12001 | <1% | 345 | $71K | |
| 83880 | <1% | 8,727 | $65K | |
| 29125 | <1% | 486 | $63K | |
| 71250 | <1% | 1,161 | $61K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 74,489 | $55K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 486 | $53K |
| 70486 | <1% | 1,212 | $52K | |
| 97165 | <1% | 556 | $52K | |
| 97016 | <1% | 1,937 | $51K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,958 | $43K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 785 | $42K |
| 84703 | <1% | 17,811 | $41K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,640 | $40K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 37,309 | $39K |
| 77065 | Tomosynthesis, mammo | <1% | 895 | $38K |
| 85379 | <1% | 8,803 | $38K | |
| 73030 | <1% | 3,693 | $37K | |
| 80076 | <1% | 22,882 | $37K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,233 | $36K |
| 90715 | <1% | 1,976 | $36K | |
| 97166 | <1% | 518 | $35K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,163 | $35K |
| 77066 | Tomosynthesis, mammo | <1% | 925 | $34K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,617 | $34K |
| 97116 | <1% | 1,596 | $34K | |
| 84484 | <1% | 29,012 | $33K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 42 | $33K |
| 72110 | <1% | 1,951 | $32K | |
| 87040 | <1% | 6,135 | $30K | |
| 73564 | <1% | 4,113 | $29K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,479 | $27K |
| 73130 | <1% | 3,299 | $25K | |
| 93798 | <1% | 466 | $24K | |
| 73630 | <1% | 4,189 | $24K | |
| 73562 | <1% | 1,688 | $23K | |
| 12011 | <1% | 127 | $20K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,291 | $20K |
| 73502 | <1% | 2,417 | $20K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,414 | $20K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 294 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,337 | $20K |
| 76536 | <1% | 193 | $20K | |
| 76942 | <1% | 433 | $19K | |
| 82962 | <1% | 19,110 | $18K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,437 | $17K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 173 | $17K |
| 72100 | <1% | 1,544 | $17K | |
| 73610 | <1% | 3,399 | $17K | |
| 93976 | <1% | 673 | $16K | |
| 85027 | <1% | 10,351 | $15K | |
| 64450 | <1% | 96 | $15K | |
| 81001 | <1% | 37,200 | $14K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,501 | $14K |
| 73110 | <1% | 1,990 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 25,393 | $14K |
| 85610 | <1% | 8,593 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,823 | $13K |
| 88304 | <1% | 391 | $13K | |
| 76801 | <1% | 188 | $12K | |
| 71271 | <1% | 115 | $11K | |
| 36430 | <1% | 51 | $10K | |
| 74018 | <1% | 1,218 | $10K | |
| 72050 | <1% | 474 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,222 | $10K |
| 94799 | <1% | 2,248 | $9K | |
| 76870 | <1% | 121 | $9K | |
| 70496 | <1% | 46 | $9K | |
| 83605 | <1% | 7,879 | $9K | |
| 86900 | <1% | 4,117 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,904 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,170 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,469 | $7K |
| 73560 | <1% | 326 | $7K | |
| 85014 | <1% | 9,552 | $6K | |
| 87081 | <1% | 5,161 | $6K | |
| 73140 | <1% | 885 | $6K | |
| 81003 | <1% | 21,088 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 655 | $6K |
| 87070 | <1% | 635 | $6K | |
| 83690 | <1% | 19,594 | $6K | |
| 96376 | <1% | 9,554 | $6K | |
| 82565 | <1% | 3,687 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,545 | $5K |
| 81025 | <1% | 15,906 | $5K | |
| 80061 | Lipid panel | <1% | 2,220 | $5K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 19 | $5K |
| 93880 | <1% | 55 | $5K | |
| 84702 | <1% | 5,205 | $5K | |
| 99234 | <1% | 109 | $5K | |
| 12002 | <1% | 27 | $5K | |
| 83735 | <1% | 6,780 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,771 | $5K |
| 74183 | <1% | 16 | $5K | |
| 73080 | <1% | 849 | $4K | |
| 97163 | <1% | 68 | $4K | |
| 77080 | <1% | 54 | $4K | |
| 77336 | <1% | 65 | $4K | |
| 86850 | <1% | 2,579 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,949 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,114 | $3K |
| 87077 | <1% | 6,445 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,501 | $3K |
| 29130 | <1% | 13 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 24,611 | $3K |
| 29515 | <1% | 16 | $3K | |
| 86901 | <1% | 4,124 | $3K | |
| 76937 | <1% | 124 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,021 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,691 | $2K |
| 87210 | <1% | 10,042 | $2K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 18 | $2K |
| 73590 | <1% | 888 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 7,264 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,596 | $2K |
| 87186 | <1% | 4,266 | $2K | |
| 85730 | <1% | 3,393 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 291 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,719 | $2K |
| 97113 | <1% | 47 | $2K | |
| 72040 | <1% | 71 | $2K | |
| 82077 | <1% | 5,520 | $2K | |
| 73090 | <1% | 347 | $2K | |
| 80143 | <1% | 234 | $2K | |
| 97750 | <1% | 87 | $2K | |
| 74022 | <1% | 689 | $1K | |
| 82553 | <1% | 447 | $1K | |
| 82607 | <1% | 233 | $1K | |
| 87631 | <1% | 71 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 22 | $1K |
| 84145 | <1% | 446 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,046 | $1K |
| 70498 | <1% | 33 | $1K | |
| 84100 | <1% | 1,186 | $1K | |
| 83970 | <1% | 187 | $1K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,284 | $1K |
| 73221 | <1% | 15 | $1K | |
| 74174 | <1% | 15 | $1K | |
| 92610 | <1% | 16 | $1K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 233 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,517 | $961.64 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,207 | $945.98 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,715 | $904.69 |
| 87634 | <1% | 69 | $805.99 | |
| 88307 | <1% | 78 | $802.16 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,781 | $780.10 |
| 85018 | <1% | 804 | $729.61 | |
| 82310 | <1% | 4,348 | $723.57 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,313 | $675.47 |
| 82728 | <1% | 123 | $634.95 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,163 | $634.25 |
| 86923 | <1% | 107 | $623.81 | |
| 72070 | <1% | 47 | $622.59 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,080 | $588.88 |
| 84439 | <1% | 153 | $587.43 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,962 | $583.46 |
| 80069 | <1% | 127 | $577.22 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 875 | $570.89 |
| 84550 | <1% | 1,049 | $555.49 | |
| 74019 | <1% | 68 | $546.65 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 809 | $534.79 |
| 71101 | <1% | 62 | $530.98 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,468 | $516.22 |
| 83615 | <1% | 932 | $484.92 | |
| 80179 | <1% | 145 | $483.55 | |
| 36600 | <1% | 99 | $341.03 | |
| 82550 | <1% | 1,431 | $330.95 | |
| 74220 | <1% | 12 | $313.41 | |
| 94729 | <1% | 15 | $312.19 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,831 | $311.24 |
| 86140 | <1% | 169 | $310.01 | |
| 82803 | <1% | 966 | $298.63 | |
| 73060 | <1% | 31 | $288.34 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,531 | $277.00 |
| 83550 | <1% | 178 | $257.18 | |
| 97802 | <1% | 12 | $256.85 | |
| 84520 | <1% | 480 | $253.23 | |
| 83540 | <1% | 221 | $208.22 | |
| 73552 | <1% | 27 | $200.83 | |
| 85652 | <1% | 235 | $182.51 | |
| 96367 | <1% | 16 | $181.56 | |
| 93246 | <1% | 14 | $171.34 | |
| 90686 | <1% | 33 | $147.73 | |
| 73660 | <1% | 42 | $145.15 | |
| G0008 | Administration of influenza virus vaccine | <1% | 419 | $134.28 |
| 84450 | <1% | 262 | $132.83 | |
| 73620 | <1% | 12 | $128.61 | |
| 84460 | <1% | 259 | $120.18 | |
| 82570 | <1% | 143 | $113.80 | |
| 87205 | <1% | 645 | $113.24 | |
| 82043 | <1% | 124 | $105.51 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 16 | $92.91 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,370 | $90.00 |
| 84156 | <1% | 101 | $81.30 | |
| 80320 | <1% | 86 | $75.81 | |
| J1815 | Injection, insulin, per 5 units | <1% | 505 | $73.85 |
| 36000 | <1% | 14 | $65.12 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,730 | $60.74 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 817 | $51.86 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 223 | $51.17 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 212 | $27.04 |
| 84132 | <1% | 95 | $26.59 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 355 | $21.54 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 264 | $18.51 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 549 | $17.71 |
| 82330 | <1% | 66 | $15.59 | |
| 85046 | <1% | 237 | $15.27 | |
| 87807 | <1% | 100 | $14.36 | |
| 82272 | <1% | 352 | $12.72 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 575 | $11.91 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 108 | $10.06 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 423 | $9.69 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 53 | $8.00 |
| 82746 | <1% | 27 | $7.20 | |
| C1769 | Guide wire | <1% | 728 | $7.15 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 156 | $6.34 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 88 | $4.12 |
| 85045 | <1% | 42 | $3.67 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 81 | $2.82 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 640 | $2.13 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 343 | $1.54 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 596 | $1.28 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 392 | $0.98 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 86 | $0.31 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 2,075 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 213 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 330 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 134 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 544 | $0.00 |
| 90653 | 0% | 56 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 101 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 134 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 254 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 208 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 307 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 124 | $0.00 |
| 90756 | 0% | 42 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 469 | $0.00 |
| C1729 | Catheter, drainage | 0% | 366 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 81 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 67 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 25 | $0.00 |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | 0% | 19 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 296 | $0.00 |
| 82009 | 0% | 17 | $0.00 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 19 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 21 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 166 | $0.00 |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 2,732 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 155 | $0.00 |
| 36416 | 0% | 295 | $0.00 | |
| A6443 | Conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to three inches and less than five inches, per yard | 0% | 550 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 18 | $0.00 |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | 0% | 40 | $0.00 |
| 88342 | 0% | 58 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 94 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 59 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 24 | $0.00 |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 18 | $0.00 |
| 90694 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.